[go: up one dir, main page]

WO2007027178A3 - Lyophilized platelet rich plasma for the use in wound healing and bone or tissue grafts or repair - Google Patents

Lyophilized platelet rich plasma for the use in wound healing and bone or tissue grafts or repair Download PDF

Info

Publication number
WO2007027178A3
WO2007027178A3 PCT/US2005/031117 US2005031117W WO2007027178A3 WO 2007027178 A3 WO2007027178 A3 WO 2007027178A3 US 2005031117 W US2005031117 W US 2005031117W WO 2007027178 A3 WO2007027178 A3 WO 2007027178A3
Authority
WO
WIPO (PCT)
Prior art keywords
bone
rich plasma
platelet rich
repair
wound healing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2005/031117
Other languages
French (fr)
Other versions
WO2007027178A2 (en
Inventor
Mackie J Walker Jr
James Bennie Gandy
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to PCT/US2005/031117 priority Critical patent/WO2007027178A2/en
Priority to BRPI0520502-6A priority patent/BRPI0520502A2/en
Priority to EP05793313A priority patent/EP1943349A2/en
Priority to CA002621140A priority patent/CA2621140A1/en
Publication of WO2007027178A2 publication Critical patent/WO2007027178A2/en
Publication of WO2007027178A3 publication Critical patent/WO2007027178A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/07—Retinol compounds, e.g. vitamin A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/203—Retinoic acids ; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/7036—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/16—Blood plasma; Blood serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/19—Platelets; Megacaryocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4833—Thrombin (3.4.21.5)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Inorganic Chemistry (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Materials For Medical Uses (AREA)

Abstract

This invention relates to an improved lyophilized platelet rich plasma used to make a platelet gel wound healant, and methods of preparation and use thereof for healing wounds are disclosed. the improved wound healant comprises therapeutically effective amounts of activated growth factors, platelet ghost, plasma (know as the plasma back bone), white blood cells with optional none, one or more additional anti-oxidant such as vitamin A and/or c and/or E, and/or none one or more antibiotics and/or GHK-Cu.
PCT/US2005/031117 2005-08-30 2005-08-30 Lyophilized platelet rich plasma for the use in wound healing and bone or tissue grafts or repair Ceased WO2007027178A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
PCT/US2005/031117 WO2007027178A2 (en) 2005-08-30 2005-08-30 Lyophilized platelet rich plasma for the use in wound healing and bone or tissue grafts or repair
BRPI0520502-6A BRPI0520502A2 (en) 2005-08-30 2005-08-30 dehydrated composition usable for mammal therapy, wound healing composition, wound healing method, wound healing, and wound healing method
EP05793313A EP1943349A2 (en) 2005-08-30 2005-08-30 Lyophilized platelet rich plasma for the use in wound healing and bone or tissue grafts or repair
CA002621140A CA2621140A1 (en) 2005-08-30 2005-08-30 Lyophilized platelet rich plasma for the use in wound healing and bone or tissue grafts or repair

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2005/031117 WO2007027178A2 (en) 2005-08-30 2005-08-30 Lyophilized platelet rich plasma for the use in wound healing and bone or tissue grafts or repair

Publications (2)

Publication Number Publication Date
WO2007027178A2 WO2007027178A2 (en) 2007-03-08
WO2007027178A3 true WO2007027178A3 (en) 2007-09-20

Family

ID=37809308

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/031117 Ceased WO2007027178A2 (en) 2005-08-30 2005-08-30 Lyophilized platelet rich plasma for the use in wound healing and bone or tissue grafts or repair

Country Status (4)

Country Link
EP (1) EP1943349A2 (en)
BR (1) BRPI0520502A2 (en)
CA (1) CA2621140A1 (en)
WO (1) WO2007027178A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090223080A1 (en) * 2007-03-19 2009-09-10 Hemcon Medical Technologies, Inc. Apparatus and methods for making, storing, and administering freeze-dried materials such as freeze-dried plasma
US8449520B2 (en) 2007-03-19 2013-05-28 HemCon Medical Technologies Inc. Apparatus and methods for making, storing, and administering freeze-dried materials such as freeze-dried plasma
EP2555613A1 (en) * 2010-04-08 2013-02-13 INSERM - Institut National de la Santé et de la Recherche Médicale Zeodration method for the preservation of blood platelets
US20160263193A1 (en) * 2013-11-14 2016-09-15 Nte-Sener Healthcare, S.A. Method for obtaining a cytokine-rich composition and composition obtained by means of this method

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5378461A (en) * 1991-07-12 1995-01-03 Neigut; Stanley J. Composition for the topical treatment of skin damage
US20010019819A1 (en) * 2000-02-10 2001-09-06 Wolkers Willem F. Therapeutic platelets and methods
US20020114775A1 (en) * 1996-09-23 2002-08-22 Incept Llc Crosslinking agents and methods of use

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5378461A (en) * 1991-07-12 1995-01-03 Neigut; Stanley J. Composition for the topical treatment of skin damage
US20020114775A1 (en) * 1996-09-23 2002-08-22 Incept Llc Crosslinking agents and methods of use
US20010019819A1 (en) * 2000-02-10 2001-09-06 Wolkers Willem F. Therapeutic platelets and methods

Also Published As

Publication number Publication date
CA2621140A1 (en) 2007-03-08
WO2007027178A2 (en) 2007-03-08
BRPI0520502A2 (en) 2009-06-13
EP1943349A2 (en) 2008-07-16

Similar Documents

Publication Publication Date Title
WO2006052451A3 (en) Implantable collagen compositions
WO2008019128A3 (en) Solid dressing for treating wounded tissue
WO2009100280A3 (en) 3-dimensional silk hydroxyapatite compositions
DE502004007735D1 (en) Flächiges implantat
WO2009075882A3 (en) Impaired wound healing compositions and treatments
WO2008157733A3 (en) Fibrin gel for controlled release of pdgf and uses thereof
EP2289535B8 (en) Compositions and methods for promoting wound healing and tissue regeneration
EP2497478A3 (en) Oligosaccaride compositions and use thereof in the treatment of infection
WO2008060622A3 (en) Improved methods and compositions for wound healing
WO2003015612A3 (en) Materials and methods to promote repair of nerve tissue
WO2006118801A3 (en) Multi-purpose medical implant devices
WO2008130989A3 (en) Prosthetic implants
WO2009123720A3 (en) Methods and compositions for medical articles produced from proteinaceous compounds
WO2010052007A3 (en) Surgical suture material with barbs cut into it in the undrawn state
WO2008034013A3 (en) Medical devices and methods of making the same
EP2540301A3 (en) Methods and pharmaceutical compositions for healing wounds
WO2006031398A3 (en) Compositions containing fast-leaching plasticizers for improved performance of medical devices
EP1795213A3 (en) Implantable microbial cellulose materials for various medical applications
WO2006138468A3 (en) Use of vegf for wound healing
CL2008001171A1 (en) Pharmaceutical composition comprising fibrinogen, thrombin and a compound containing strontium; and its use in the treatment of a diseased, damaged, deficient or defective bone.
WO2017200659A3 (en) A method to enhance wound healing using silk-derived protein
ATE466583T1 (en) VISCOELASTIC SUBSTANCES FOR USE IN MIDDLE EAR SURGERY
WO2008130607A3 (en) Wound healing compositions containing keratin biomaterials
WO2007061939A3 (en) Metabolite derivatives of the hdac inhibitor fk228
WO2006081435A3 (en) Method of providing readily available cellular material derived from cord blood, and a composition thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
ENP Entry into the national phase

Ref document number: 2621140

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: MX/a/2008/002958

Country of ref document: MX

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 1277/CHENP/2008

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2005793313

Country of ref document: EP

ENP Entry into the national phase

Ref document number: PI0520502

Country of ref document: BR

Kind code of ref document: A2